Bioscience Research Integration Software Platform

描述(由申请人提供)： 调查和了解与疾病有关的生物信息的所有要素的必要性现在比以往任何时候都更加明显。然而，由当今技术产生的非整合数据的雪崩阻碍了科学家有效地将这些数据减少为有意义的发现。因此，通过生物科学研究收集的大量数据没有标准化，无法在实验室之间或实验室内整合，从联邦资助的研究中获得的原始数据相对较少，尽管法规要求这样做。同样，研究人员往往希望合作，但并不是因为他们缺乏这样做的便利手段。我们的使命是通过完成一个原型软件应用程序LabmatrixTM来提高面向临床的基础生命科学研究的生产率。LabmatrixTM将为分子、基因组和临床数据的收集、操作和相互关系提供一个基于软件的平台，从而提高发现和验证分子靶标的效率。除了为生命科学家完成一个引人注目的软件工具外，在两个具有代表性的测试实验室中，在实施之前、期间和之后收集适当的数据，将使我们能够确定此类软件对生产率的影响。第一阶段，具体目标1将在两个测试实验室完成当前科学实践评估方案的设计，整合项目小组所有成员的观点，包括一般生产力、信息安全、参考数据的使用、工作流程和计算机用户交互。第一阶段，特定目标2a将使用在特定目标1中创建的工具完成对两个具有代表性的生物科学实验室的科学做法的评估。第一阶段，特定目标2b将评估目前的LabmatrixTM软件开发工具和做法。第一阶段，具体目标3将比较评价期间确定的生物科学生产力和满意度的关键要素与LabmatrixTM早期原型中的现有支持，并将记录新的要求。第一阶段，具体目标4a将发展具体目标2b中确定的以经验为基础的软件开发工具和做法的使用，并将建立一个定期观察/记录周期，以衡量其影响。第一阶段，特定目标4b将完成第二阶段实施所需的软件实践更改。第一阶段，特定目标5实施LabmatrixTM的主要功能，以优化在各种生物科学实验室中实施的简易性。LabmatrixTM的关键创新是将实验室中常见的科学实践捕获到一个集成的软件包中，从而实现数据的广泛共享和重复使用，这是实验室实践工作流管理在该行业尚未完全完成的一个步骤。与这些具体目标相关的里程碑的实现将标志着第一阶段的结束和第二阶段的开始，届时LabmatrixTM将通过两个测试实验室的持续互动软件开发为商业推出做好准备。

DESCRIPTION (provided by applicant): The need to investigate and understand all elements of biological information pertinent to disease is more clearly evident now than ever before. However, the avalanche of non-integrated data produced by today's technologies prevents scientists from effectively reducing these data to meaningful discoveries. As a result, the vast bulk of data collected through bioscience research are not standardized and cannot be integrated between or within laboratories, and relatively few raw data are available from federally-funded research, despite a regulation requiring it. In the same vein, researchers often wish to collaborate, but do not because they lack a convenient means to do so. Our mission is to improve clinically-oriented basic life science research productivity by completing a prototype software application, LabmatrixTM. LabmatrixTM will provide a software-based platform for the collection, manipulation and interrelation of molecular, genomic and clinical data that results in increased efficiency in discovering and validating molecular targets. In addition to completion of a compelling software tool for life scientists, the collection of appropriate data before, during, and after implementation in two representative Test Laboratories will allow us to ascertain the impact on productivity of such software. Phase I, Specific Aim 1 will complete design of a current scientific practices evaluation protocol in two test laboratories, integrating viewpoints from all members of the project team, including general productivity, information security, use of reference data, workflow, and computer-user interactions. Phase I, Specific Aim 2a will complete evaluation of scientific practices in two representative bioscience laboratories using the tool created in Specific Aim 1. Phase I, Specific Aim 2b will evaluate current LabmatrixTM software development tools and practices. Phase I, Specific Aim 3 will compare key elements of bioscience productivity and satisfaction identified during the evaluation period to existing support in the LabmatrixTM early prototype, and will document new requirements. Phase I, Specific Aim 4a will evolve the use of empirically-based software development tools and practices identified in Specific Aim 2b, and will establish a regular observation/documentation cycle to measure their impact. Phase I, Specific Aim 4b will complete software practice changes needed for implementation in Phase II. Phase I, Specific Aim 5 implements key features of LabmatrixTM to optimize the ease of implementation in varied bioscience laboratories. The key LabmatrixTM innovation is the capture of scientific practices common across labs into one integrated software package that enables broad sharing and re-use of data, a step in laboratory practices workflow management not yet fully accomplished in this industry. Achievement of milestones linked to these Specific Aims will mark the end of Phase I and commencement of Phase II, where LabmatrixTM will be readied for commercial launch through continued interactive software development in two test laboratories.